![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/9/95/Fedratinib.svg/640px-Fedratinib.svg.png&w=640&q=50)
Fedratinib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Fedratinib?
Summarize this article for a 10 year old
Fedratinib, sold under the brand name Inrebic, is an anti-cancer medication used to treat myeloproliferative diseases including myelofibrosis.[5] It is used in the form of fedratinib hydrochloride capsules that are taken by mouth. It is a semi-selective inhibitor of Janus kinase 2 (JAK-2).[5][6] It was approved by the FDA on 16 August 2019.[5]
![]() | |
Clinical data | |
---|---|
Trade names | Inrebic |
Other names | SAR302503; TG101348 |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | By mouth |
Drug class | Antineoplastic agent |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H36N6O3S |
Molar mass | 524.68 g·mol−1 |
3D model (JSmol) | |
Density | 1.247 ± 0.06 g/cm3 |
| |
| |
![]() ![]() |
Myelofibrosis is a myeloid cancer associated with anemia, splenomegaly, and constitutional symptoms. Patients with myelofibrosis frequently harbor mutations which activate the JAK-STAT signaling pathway and which are sensitive to fedratinib. Phase I trial results focused on safety and efficacy of fedratinib in patients with high- or intermediate-risk primary or post–polycythemia vera/essential thrombocythemia myelofibrosis have been published in 2011.[7]